Literature DB >> 21826666

Increased midkine expression correlates with desmoid tumour recurrence: a potential biomarker and therapeutic target.

Chiara Colombo1, Chad J Creighton, Markus P Ghadimi, Svetlana Bolshakov, Carla L Warneke, Yiqun Zhang, Kristelle Lusby, Shirley Zhu, Alexander J Lazar, Robert B West, Matt van de Rijn, Dina Lev.   

Abstract

Desmoid tumours (DTs) are soft tissue monoclonal neoplasms exhibiting a unique phenotype, consisting of aggressive local invasiveness without metastatic capacity. While DTs can infrequently occur as part of familial adenomatosis polyposis, most cases arise sporadically. Sporadic DTs harbour a high prevalence of CTNNB1 mutations and hence increased β-catenin signalling. However, β-catenin downstream transcriptional targets and other molecular deregulations operative in DT inception and progression are currently not well defined, contributing to the lack of sensitive molecular prognosticators and efficacious targeted therapeutic strategies. We compared the gene expression profiles of 14 sporadic DTs to those of five corresponding normal tissues and six solitary fibrous tumour specimens. A DT expression signature consisting of 636 up- and 119 down-regulated genes highly enriched for extracellular matrix, cell adhesion and wound healing-related proteins was generated. Furthermore, 98 (15%) of the over-expressed genes were demonstrated to contain a TCF/LEF consensus binding site in their promoters, possibly heralding direct β-catenin downstream targets relevant to DT. The protein products of three of the up-regulated DT genes: ADAM12, MMP2 and midkine, were found to be commonly expressed in a large cohort of human DT samples assembled on a tissue microarray. Interestingly, enhanced midkine expression significantly correlated with a higher propensity and decreased time for primary DT recurrence (log-rank p = 0.0025). Finally, midkine was found to enhance the migration and invasion of primary DT cell cultures. Taken together, these studies provide insights into potential DT molecular aberrations and novel β-catenin transcriptional targets. Further studies to confirm the utility of midkine as a clinical DT molecular prognosticator and a potential therapeutic target are therefore warranted. Raw gene array data can be found at: http://smd.stanford.edu/
Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21826666     DOI: 10.1002/path.2951

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  11 in total

1.  CRISPR-SID: Identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping.

Authors:  Thomas Naert; Dieter Tulkens; Tom Van Nieuwenhuysen; Joanna Przybyl; Suzan Demuynck; Matt van de Rijn; Mushriq Al-Jazrawe; Benjamin A Alman; Paul J Coucke; Kim De Leeneer; Christian Vanhove; Savvas N Savvides; David Creytens; Kris Vleminckx
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-23       Impact factor: 12.779

2.  In-depth characterization of the secretome of colorectal cancer metastatic cells identifies key proteins in cell adhesion, migration, and invasion.

Authors:  Rodrigo Barderas; Marta Mendes; Sofia Torres; Rubén A Bartolomé; María López-Lucendo; Roi Villar-Vázquez; Alberto Peláez-García; Eduardo Fuente; Félix Bonilla; J Ignacio Casal
Journal:  Mol Cell Proteomics       Date:  2013-02-26       Impact factor: 5.911

Review 3.  Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review.

Authors:  Thomas D McLean; Serena Duchi; Claudia Di Bella
Journal:  Target Oncol       Date:  2022-04-21       Impact factor: 4.864

4.  A Mesenteric Desmoid Tumor with Rapid Progression.

Authors:  Kazunao Hayashi; Masaaki Takamura; Hisashi Yokoyama; Yuichi Sato; Satoshi Yamagiwa; Hitoshi Nogami; Toshifumi Wakai; Go Hasegawa; Shuji Terai
Journal:  Intern Med       Date:  2017-03-01       Impact factor: 1.271

5.  β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression.

Authors:  Chiara Colombo; Antonino Belfiore; Nicholas Paielli; Loris De Cecco; Silvana Canevari; Erik Laurini; Maurizio Fermeglia; Sabrina Pricl; Paolo Verderio; Stefano Bottelli; Marco Fiore; Silvia Stacchiotti; Elena Palassini; Alessandro Gronchi; Silvana Pilotti; Federica Perrone
Journal:  Mol Oncol       Date:  2017-09-29       Impact factor: 6.603

6.  Tumor location determines midkine level and its association with the disease progression in colorectal cancer patients: a pilot study.

Authors:  Malgorzata Krzystek-Korpacka; Dorota Diakowska; Krzysztof Grabowski; Andrzej Gamian
Journal:  Int J Colorectal Dis       Date:  2012-05-06       Impact factor: 2.571

7.  The Wnt/β-catenin pathway in human fibrotic-like diseases and its eligibility as a therapeutic target.

Authors:  Maria Vittoria Enzo; Marco Rastrelli; Carlo Riccardo Rossi; Uros Hladnik; Daniela Segat
Journal:  Mol Cell Ther       Date:  2015-01-30

8.  Targeting the Notch pathway: A potential therapeutic approach for desmoid tumors.

Authors:  Hui Shang; Danielle Braggio; Ya-Jung Lee; Ghadah A Al Sannaa; Chad J Creighton; Svetlana Bolshakov; Alexander J F Lazar; Dina Lev; Raphael E Pollock
Journal:  Cancer       Date:  2015-09-08       Impact factor: 6.860

9.  Clinical significance of midkine expression in sporadic desmoid tumors.

Authors:  Hee Sung Kim; Jin Kim; Kyung Han Nam; Woo Ho Kim
Journal:  Oncol Lett       Date:  2016-01-19       Impact factor: 2.967

10.  Prognostic value of Midkine expression in patients with solid tumors: a systematic review and meta-analysis.

Authors:  Luo Zhang; Xing Song; Yingjie Shao; Changping Wu; Jingting Jiang
Journal:  Oncotarget       Date:  2018-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.